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Killer immunoglobulin-like receptor (KIR) recognition of specific human histocompatibility 
leukocyte antigen (HLA) class I allotypes contributes to the array of receptor–ligand 
interactions that determine natural killer (NK) cell response to its target. Contrasting 
genetic effects of 
 
KIR
 
/
 
HLA
 
 combinations have been observed in infectious and autoimmune 
diseases, where genotypes associated with NK cell activation seem to be protective or to 
confer susceptibility, respectively. We show here that combinations of 
 
KIR
 
 and 
 
HLA
 
 loci also 
affect the risk of developing cervical neoplasia. Specific inhibitory 
 
KIR
 
/
 
HLA
 
 ligand pairs 
decrease the risk of developing neoplasia, whereas the presence of the activating receptor 
 
KIR3DS1
 
 results in increased risk of disease, particularly when the protective inhibitory 
combinations are missing. These data suggest a continuum of resistance conferred by NK 
cell inhibition to susceptibility involving NK cell activation in the development of cervical 
neoplasia and underscore the pervasive influence of 
 
KIR
 
/
 
HLA
 
 genetic variation in human 
disease pathogenesis.
 
NK cells are an important component of the
innate immune system, providing the first line
of defense in the early stages of the immune
response against viral infections and tumors by
production of cytokines or direct cytotoxicity
(1, 2). NK cell activity is controlled partially
through interactions between killer immuno-
globulin-like receptor (KIR) expressed on NK
cells and their respective HLA class I ligands
expressed on target cells (3–5). 
 
HLA
 
 class I loci
are characterized by extreme allelic polymor-
phism, whereas 
 
KIR
 
 variation stems both from
the polygenic nature of 
 
KIR
 
 haplotypes (i.e.,
they vary in the number and types of genes
present) and from allelic polymorphism at
some of the 
 
KIR
 
 genes (6, 7). Independent
segregation of 
 
HLA
 
 (6p21) and 
 
KIR
 
 (19q13.4)
genes along with KIR specificity for particular
HLA allotypes raises the possibility that any
given individual may express KIR molecules
for which no ligand is present or vice versa, re-
sulting in the lack of NK cell signaling through
that specific KIR. Thus, the requirement for
specific ligand–receptor interactions at these
two polymorphic loci implies an epistatic rela-
tionship (i.e., a synergistic relationship involv-
ing variation at two or more loci, specific
combinations of which are essential for the
phenotype to occur) between KIR and HLA
in NK cell–mediated immunity.
 
KIR
 
 genes encode molecules that convey
either inhibitory or activating signals to NK
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cells and to a subset of CD8
 
 
 
 T cells. Binding of inhibitory
KIR (designated 2DL and 3DL) to specific HLA allotypes has
been clearly demonstrated (3, 8), correlating with their ability
to inhibit NK cytolysis of target cells bearing those HLA mol-
ecules. The inhibitory KIR3DL1 binds HLA-B allotypes that
have the Bw4 epitope (determined by amino acid positions
79–83 of the molecule) (9). The ligand for KIR3DS1, an acti-
vating KIR that shows 99% amino acid sequence similarity to
KIR3DL1 in its extracellular domains, has not been deter-
mined, and, indeed, its cell surface expression has not been
definitively shown. However, the presence of this gene along
with 
 
HLA-B
 
 alleles encoding Bw4 have an epistatic protec-
tive effect on AIDS progression (10), suggesting that, like
KIR3DL1, KIR3DS1 might recognize some Bw4 allotypes in
HIV
 
 
 
 individuals. Specificity of inhibitory KIR for HLA-Cw
allotypes is dictated to a large extent by the presence of aspar-
agine or lysine at position 80 of the HLA-Cw molecule (11,
12). KIR2DL1 recognizes group 2 HLA-Cw molecules that
are characterized by Lys80, whereas KIR2DL2 and KIR2DL3
(referred to as KIR2DL2/3 throughout the remainder of the
paper) prefer group 1 HLA-Cw molecules containing Asn80.
 
KIR2DL1
 
, 
 
KIR2DL2/3
 
, and 
 
KIR3DL1
 
 are present in nearly
all individuals of European descent, so the presence or absence
of their HLA ligands determines the functional significance of
these inhibitory KIR in any given individual.
The effect of genetic variation at the 
 
KIR
 
 locus in com-
bination with genes encoding their HLA ligands on cancer
has not been studied previously, even though variation at
these genes may be important in the development of cancers
that are linked to viruses because 
 
KIR
 
 genes have been
shown to be associated with outcome to viral infections (10,
13). To test the possibility that the 
 
KIR
 
 genes are involved
in risk of developing cervical neoplasia, a cancer caused by
human papilloma virus (HPV; reference 14), we examined
 
KIR
 
 and 
 
HLA
 
 in three large cervix studies.
 
RESULTS AND DISCUSSION
 
To test the possibility that the 
 
KIR
 
 genes are involved in risk
of developing cervical neoplasia, a cancer caused by HPV
(14), we grouped 
 
HLA-B
 
 (
 
HLA-B Bw4
 
) and 
 
HLA-Cw
 
(groups 1 and 2) class I alleles according to KIR ligand spec-
ificity using 
 
HLA
 
 genotypes determined previously from
participants in three large cervical studies and compared the
 
HLA
 
 group frequencies in cytologically normal versus cervi-
cal intraepithelial neoplasia 3 (CIN3)/cancer patients. Using
a dominant model, both 
 
HLA-Cw
 
 group 2 and 
 
HLA-B Bw4
 
allelic groups were significantly associated with a decreased
risk of disease when data from the three studies were merged
(odds ratio [OR] 
 
 
 
 0.71, P
 
 
 
 
 
 0.02, and OR 
 
 
 
 0.70, P
 
 
 
 
 
0.015, respectively; Fig. 1 and Table S1, available at http://
www.jem.org/cgi/content/full/jem.20042158/DC1), a
trend that was reflected in each individual study (although
not significantly in most comparisons) and either consistent
or more pronounced when restricted to HPV
 
 
 
 controls (Cw
group 2, OR 
 
 
 
 0.77, 95% confidence interval 
 
 
 
 0.53–1.12;
Bw4, OR 
 
 
 
 0.56, 95% confidence interval 
 
 
 
 0.38–0.81).
Although we cannot entirely rule out the possible association
between these alleles and HPV infection, the observation of
similar associations in HPV-restricted controls supports a
role for these alleles in cervical cancer pathogenesis. The
presence of both 
 
Bw4
 
 and 
 
Cw
 
 group 2 showed a somewhat
stronger effect than the presence of an allele or alleles from
only one of these groups (OR 
 
 
 
 0.56, P
 
 
 
 
 
 0.002 for both,
vs. OR 
 
 
 
 0.65, P 
 
 
 
 0.024 for only one; Table I). Alterna-
tively, the presence of at least one copy of 
 
Cw
 
 group 1 was
significantly associated with increased risk of disease in the
Eastern U.S. study (OR 
 
 
 
 2.14, P 
 
 
 
 0.02) but not in the
Costa Rica or Portland studies (Table S1). However, 
 
Cw
 
group 1 in the absence of both 
 
Cw
 
 group 2 and 
 
Bw4
 
 did
associate with susceptibility in each of the three studies
(OR 
 
 
 
 1.47–2.09), although, again, significance was reached
Figure 1. Independent associations between HLA ligands for KIR 
and CIN3/cancer outcome in three independent studies. Odds ratios 
(circle) and 95% confidence intervals (dashes) are shown separately for 
HLA-Cw group 2 and HLA-B Bw4, for the Eastern U.S., Costa Rica, and 
Portland studies, followed by estimates for data from all three studies 
merged. 
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only in the Eastern U.S. study (for merged data, OR 
 
 
 
 1.6,
P 
 
 
 
 0.0066). Overall, these data suggest that one mode of
influence conferred by HLA class I on cervical neoplasia may
stem from their capacity as ligands for inhibitory KIR mole-
cules (inhibitory 
 
KIR
 
 genes that encode products recogniz-
ing Cw group 1, Cw group 2, and Bw4 are present in 
 
 
 
95%
of individuals studied here). Specifically, effector cell inhibi-
tion mediated by KIR2DL1 and KIR3DL1 (the receptors
for Cw group 2 and Bw4, respectively) may participate in
decreasing the risk of cervical neoplasia.
Unlike several of the inhibitory 
 
KIR
 
, the activating 
 
KIR
 
are present on only a fraction of 
 
KIR
 
 haplotypes. Given the
protective influence of 
 
Bw4
 
 and 
 
Cw
 
 group 2 alleles, which
encode the high-affinity ligands for two inhibitory KIR, we
hypothesized that the presence of activating 
 
KIR
 
 may confer
a susceptibility effect. Two of the three cervix studies from
which DNA was available (Eastern U.S. and Costa Rica)
were typed for the presence or absence of six activating
and five inhibitory 
 
KIR
 
 genes, which, along with three
anchor 
 
KIR
 
 loci that are always present, constitute the
known assortment of 
 
KIR
 
 haplotypes (Table S2, available at
http://www.jem.org/cgi/content/full/jem.20042158/DC1).
 
KIR3DS1
 
, an activating receptor that shows high sequence
similarity to 
 
KIR3DL1
 
, was observed significantly more fre-
quently in CIN3/cancer cases than in controls (OR 
 
 
 
 1.64,
P
 
 
 
 
 
 0.009). The activating 
 
KIR
 
 genes, 
 
KIR2DS1
 
 and
 
KIR2DS5
 
, showed a weak association with increased risk of
CIN3/cancer that bordered on significance (Table S2), pos-
sibly because of their strong linkage disequilibrium with
 
KIR3DS1
 
 (15, 16). Thus, activating and inhibitory 
 
KIR
seem to have opposing effects on the risk of developing cer-
vical neoplasia.
When effects of KIR3DS1 were evaluated jointly with
Cw group 2 (Fig. 2, left) or Bw4 (Fig. 2, right), a significant
gradient of effects from susceptibility to protection was ob-
served in the following order (Fig. 2 and Table S3, available
at http://www.jem.org/cgi/content/full/jem.20042158/DC1):
(a) presence of KIR3DS1 in the absence of ligand for the in-
hibitory KIR2DL1 or KIR3DL1 (OR   1; baseline), (b)
absence of both activating KIR3DS1 and inhibitory KIR
ligand (OR   0.69–0.81), (c) presence of both KIR3DS1
and inhibitory KIR ligand (OR   0.60–0.67), and (d) ab-
sence of KIR3DS1 in the presence of inhibitory KIR
ligand (OR   0.44–0.47). These trends were evident for
KIR3DS1 in combination with Cw group 2 (ligand for
KIR2DL1; P trend   0.0026) as well as Bw4 (ligand
for KIR3DL1; P trend   0.0025), supporting a scenario in
which the risk of developing cervical neoplasia is, to some
extent, a function of the level of NK cell activation contrib-
uted by KIR.
Table I. Combined effect of HLA-B Bw4 and HLA-Cw group 2 
on CIN3 cancer
Merged
KIR/HLA
Cases
(n   257)
Controls
(n   675)
OR 
(95% CI) p-value
n (%) n (%)
Bw4 /Grp2  75 (29) 134 (20) 1.00 (ref) –
Bw4 /Grp2 
or Bw4 /Grp2 
87 (34) 239 (35) 0.65 (0.45–0.95) 0.0243
Bw4 /Grp2  95 (37) 302 (45) .56 (0.30–0.81) 0.0020
CI, confidence interval; OR, odds ratio.
Figure 2. Effect of compound genotypes KIR 3DS1/ HLA-Cw group 
2 and KIR3DS1/HLA-B Bw4 on CIN3/cancer. Odds ratios (circle) and 
95% confidence intervals (dashes) are shown separately for KIR 3DS1 and 
HLA-Cw group 2, and for KIR3DS1 and HLA-B Bw4. The referent groups, 
KIR3DS1 /Cw group 2  (left) and KIR3DS1 /HLA-B Bw4  (right), are those 
with which all other genotypically defined groups are compared, and the 
odds ratio for each referent group is set at 1. Middle genotypes in both 
analyses were grouped together to generate the P trend values because 
we have no functional criteria to suggest that one genetic factor (HLA-Cw 
group 2, HLA-B Bw4, or KIR3DS1) is dominant over the others. We list the 
various genotypes separately and ordered by decreasing odds ratios as a 
means to compare odds ratios of individual genotypes.KIR AND HLA IN CERVICAL NEOPLASIA | Carrington et al. 1072
The HLA-B and -C loci are in strong linkage disequilib-
rium, being separated by only 81.5 kb. Indeed, HLA-B Bw4
and HLA-Cw group 2 are in significant but not complete
linkage disequilibrium (D [Q2]    0.413, P   0.0001).
Thus, it can be difficult to distinguish between disease asso-
ciations involving one or both of these loci in the context of
their function as inhibitory KIR ligands, particularly because
the receptors that recognize these ligands, KIR3DL1 and
KIR2DL1, are present in 95–98% of all individuals (Table
S2). To address this issue with regard to the KIR3DS1/
HLA-Cw group 2 and KIR3DS1/HLA-B Bw4 associations
in cervical disease, we tested for independent and additive
effects of these compound genotypes, which were suggested
in the analysis of the HLA groups where KIR genotype was
not considered (Table I). A significant test for trend was ob-
served for odds ratios determined in a progressive manner
from genotypes expected to result in the most activation to
those resulting in the most inhibition as follows (P trend  
0.0012; Fig. 3 and Table S4, available at http://www.jem.
org/cgi/content/full/jem.20042158/DC1): (a) absence of
both Bw4 and Cw group 2, presence of KIR3DS1; (b) pres-
ence of either Bw4 or Cw group, presence of KIR3DS1; (c)
absence of Bw4 and Cw group 2, absence of KIR3DS1; (d)
presence of Bw4 and Cw group 2, presence of KIR3DS1; (e)
presence of Bw4 and/or Cw group 2, absence of KIR3DS1.
Although numbers are limited, the data suggest that having
both Bw4 and Cw group 2 may be more protective than
having only one of these inhibitory ligands when KIR3DS1
is present (compare the second and fourth sets in Fig. 3).
However, in the absence of KIR3DS1, there did not seem
to be an additive effect of having both Bw4 and Cw group 2
relative to having only one of these ligands (Bw4 alone,
OR   0.48, P   0.06; Cw group 2 alone, OR   0.43, P  
0.04; Bw4 and Cw group 2, OR   0.44, P   0.02). These
statistics also indicate independent protective effects of both
Bw4 and Cw group 2, as opposed to a single protective locus
that is simply marked by a second locus through linkage dis-
equilibrium.
Previous experimental data are consistent with the hy-
pothesis that KIR2DL1 provides a stronger inhibitory signal
than do KIR2DL2 and KIR2DL3 (17), and previously re-
ported genetic epidemiological data support this model (13,
18). We suggest that the data reported herein present an-
other illustration of the distinction among KIR2DL recep-
tors in effector cell signaling, in which KIR2DL1 binding to
Cw group 2 ligands may send a stronger inhibitory signal to
the effector cells than does KIR2DL2 or KIR2DL3 upon
binding to Cw group 1 ligands on target cells. The poten-
tially strong inhibition mediated by KIR2DL1–Cw group 2,
along with that conferred by KIR3DL1–Bw4 interactions,
may avert to some extent the immune activation, which we
propose is linked to cervical pathogenesis. A model for the
gradation of responses from most activating (susceptible) to
most inhibitory (protective) is shown in Fig. 4.
Cervical neoplasia is the third disease with which
KIR3DS1 has been associated (10), underscoring the need to
determine whether this receptor is expressed, and, if so, to
identify its ligand. Rather than being directly involved in
disease processes, KIR3DS1 may simply mark a neighboring
gene that is directly involved in pathogenesis of cervical neo-
plasia. Indeed, all individuals in this study with KIR3DS1
also had KIR2DS1. However, four individuals who had
KIR2DS1 were missing KIR3DS1, and all four were dis-
ease-free, accounting for the weaker association between
KIR2DS1 and disease (Table S2) and suggesting that
KIR2DS1 may not independently increase risk of this dis-
ease. Given the strong linkage disequilibrium among the
KIR genes, it is difficult to rule out the possibility that both
KIR2DS1 and KIR3DS1 mark another locus that directly
influences the risk of developing cervical neoplasia.
The existence of functionally opposing KIR molecules
suggests that the health benefits derived from any given acti-
vating or inhibitory KIR may be coupled to certain risks, so
that a KIR gene (or haplotype) conferring protection against
one disease may actually predispose to another. This model
is corroborated by genetic epidemiological data, which
show that specific KIR/HLA compound genotypes ex-
pected to result in an activating phenotype are associated
with protection against some infectious diseases (10, 13) but
are also associated with susceptibility to autoimmune patho-
genesis (19–21). In this regard, cervical neoplasia may more
closely resemble autoimmune disease, in spite of its infec-
tious etiology.
HPV infection is necessary, but not sufficient, for devel-
opment of cervical cancer (22). Nevertheless, HPV infec-
tions rarely progress to cervical cancer; most HPV infections
Figure 3. Combined effect of activating KIR3DS1 and HLA ligands 
(HLA-Cw group 2 and HLA-B Bw4). Odds ratios (circle) and 95% confi-
dence intervals (dashes) are shown for each combination. In this analysis, 
the genotype of the referent group (for which the odds ratio is set at 1) 
was KIR3DS1 /HLA-Cw group 2-/HLA-B Bw4 . As in Fig. 2, middle geno-
types were grouped together to generate the P trend values (Fig. 2).JEM VOL. 201, April 4, 2005 1073
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cause no or only mild cytologic abnormalities that subse-
quently regress to normalcy. Cervical inflammation does not
seem to correlate significantly with HPV infection but has
been associated with high-grade lesions in oncogenic HPV-
infected women (23). Thus, although acquired immune
responses to HPV may deter development of high-grade
lesions and cancer, inappropriate localized hyperresponsive-
ness, mediated in part by KIR–ligand interactions, may ac-
tually increase the risk of disease progression. The findings
described here indicate that further studies of the inflamma-
tory process in the progression to cervical neoplasia and of
the role of NK cells (and CTLs) in exacerbating this process
are justified.
MATERIALS AND METHODS
Study population.  Informed consent was obtained from all participants
in accordance with U.S. Department of Health and Human Services guide-
lines. The study protocol was approved by the Institutional Review Board
of the National Institutes of Health and local review boards. Participants
were selected from three cervix studies sponsored by the National Cancer
Institute and for whom specimens were available for the current investiga-
tion: a 24,000-woman cohort in Portland, Oregon (24); a 10,077-woman
population-based cohort in Guanacaste, Costa Rica (25); and a 570 woman
multicenter study of histologic subtypes of cervical neoplasia in the Eastern
U.S. (26). In brief, all cervical cancer and CIN3 cases were included from
the three studies; all controls from the U.S.-based case control study were
included, and a selected group of population-based controls were included
from the two cohort studies as previously described (24, 27, 28) for a
nested-case control design. Although HLA class I typing was completed in a
subset of all three studies, samples were available for KIR typing only in the
latter two studies. Our final analytic group for HLA analysis included 257
women with cancer (squamous cell carcinoma) or CIN3 and 675 normal
controls. Because KIR typing was not conducted in the Portland cohort
(because of lack of DNA), analysis of combinatorial KIR/HLA effects in-
cluded 196 CIN3/cancer cases and 330 controls.
HPV testing. Cervicovaginal samples were tested by PCR for HPV
DNA, as described elsewhere (24–26). In the Portland cohort, HPV was
typed with MY09/11 consensus primers using dot blot. In the Eastern U.S.
case-control study, HPV was also typed with MY09/11 consensus primers,
but by strip technology. In the Costa Rica cohort, HPV typing was done by
both PCR (with MY09/11) and the hybrid-capture tube test.
HLA genotyping.  HLA class I genotypes had been determined previously
for all three cohorts (28). Briefly, protocols involving sequence-specific oligo-
nucleotide probe hybridization developed by the 13th International Histocom-
patibility Workshop (www.ihwg.org/protocols/protocol.htm) were employed.
KIR genotyping.  DNA was available for KIR typing in participants of
the Costa Rica cohort and the study of cervical neoplasia in the Eastern
U.S. (see Study populations). Genomic DNA was genotyped for presence
or absence of the following genes: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5,
2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, and 2DP1.
Genotyping was performed using PCR amplification with two pairs of lo-
cus-specific primers (PCR-SSP) as previously described (19). Internal con-
trol primers that amplify a 796-bp fragment of the third intron of DRB1
were also included in each PCR to confirm robust PCR amplifications.
Amplification was performed in a volume of 5  l containing 200  M
dNTP, 500 nM primer, 1.5 mM MgCl2, 20 mM Tris-HCl, pH 8.4, 50 mM
KCl, and 0.5 U of Platinum Taq DNA polymerase (Invitrogen). Cycling
was performed as follows: 2 min at 94 C; 5 cycles of 94 C for 5 s, 65 C for
15 s, 72 C for 30 s; 21 cycles of 94 C for 5 s, 60 C for 15 s, 72 C for 30 s; 4
Figure 4. Model of the spectrum of KIR-mediated NK phenotypes 
associated with risk of developing cervical neoplasia. Resistance to 
cervical neoplasia increases when genotypes are ordered by their ability 
to confer the most activation (susceptibility) to the most inhibition (pro-
tection). (a) Presence of KIR3DS1 and absence of ligand for inhibitory KIR 
results in strong activation (most susceptibility). (b) Presence of KIR3DS1 
and presence of one or the other ligand for the inhibitory KIR results in 
weak activation. (c) Absence of the activating KIR3DS1, and absence of 
ligands for inhibitory KIR result in relative neutrality. (d) Presence of 
KIR3DS1 along with ligands for one or both inhibitory KIR confers weak 
inhibition. (e) Presence of ligands for inhibitory KIR in the absence of 
KIR3DS1 results in strong inhibition (most protection). Note that ex-
pression of KIR3DS1 and a potential ligand for this receptor have not 
been defined, and that its hypothetical expression and binding to a ligand 
are proposed in this model based solely on the data presented herein. Red 
shapes, activating receptor and ligand; Green shapes, inhibitory receptors 
and ligands.KIR AND HLA IN CERVICAL NEOPLASIA | Carrington et al. 1074
cycles of 94 C for 5 s, 55 C for 1 min, 72 C for 2 min; and a final extension
step of 10 min at 72 C. PCR products were electrophoresed in 2% agarose
gels containing ethidium bromide, and predicted size products were visual-
ized under ultraviolet light.
Statistical methods.  A case-control analysis was conducted in which pa-
tients with cancer or CIN3 were compared with population control sub-
jects. HLA-B Bw4, HLA-Cw group 2, and KIR genotype frequencies were
initially determined for cases and controls; ORs and 95% CIs were calcu-
lated to determine the magnitude and statistical significance of associations
(29). In merged analyses, the analyses were adjusted by study to account for
potential differences among the populations. Additional adjustment by HPV
cofactors for CIN3/cancer endpoints (smoking, parity, oral contraceptive
use) did not affect our risk estimates. Because these HPV cofactors were not
associated with KIR/HLA genotypes, we present results from the more ro-
bust, parsimonious study-adjusted model. Statistical analyses were per-
formed using SAS software (version 8.12; SAS Institute). All tests of statisti-
cal significance are 2-sided. Linkage disequilibrium between the group of
HLA-B Bw4 and the Cw group 2 alleles was tested by computing D  (30).
Online supplemental material. Table S1 shows the raw data for Fig. 1.
Table S2 shows independent associations between all KIR genes tested and
CIN3/cancer. Table S3 shows the raw data for Fig. 2 with the middle ge-
notypes considered separately (Table S3, A) and grouped together (Table
S3, B). Table S4 shows the raw data for Fig. 3 with the middle genotypes
considered separately (Table S4, A) and grouped together (Table S4, B).
Online supplemental material is available at http://www.jem.org/cgi/con-
tent/full/jem.20042158/DC1.
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